Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 07:00 ET
|
Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
ASSYSTEM: First-quarter 2024 consolidated revenue
April 25, 2024 11:35 ET
|
ASSYSTEM
First-quarter 2024 consolidated revenue: €154.3m (up 7.2%) Organic growth: 5.5% vs Q1 20232023 dividend payment calendar Paris-La Défense, 25 April 2024, 5.35 p.m. (CEST) – Assystem S.A. (ISIN:...
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024 07:00 ET
|
Arvinas Inc.
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
March 27, 2024 08:34 ET
|
TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223...
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230
March 27, 2024 08:00 ET
|
TellBio, Inc
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for...
NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health
March 18, 2024 17:16 ET
|
NVIDIA
SAN JOSE, Calif.—GTC, March 18, 2024 (GLOBE NEWSWIRE) -- NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest...
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 14, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Global Vision Transformers Industry Research 2023-2028 - Growing Impact of AI in Machine Vision Fuels Expansion of the Market
February 13, 2024 09:59 ET
|
Research and Markets
Dublin, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The "Global Vision Transformers Market by Offering (Solutions, Professional Services), Application (Image Segmentation, Object Detection, Image Captioning),...
Elastography Imaging Market Poised for Robust Growth: Comprehensive Research Forecasts a CAGR of 7.91% from 2024 to 2034
January 29, 2024 05:01 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Elastography Imaging Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. In an era where...